Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.

Autor: Trněný M; First Department of Medicine - Hematology, Charles University General Hospital, Prague, Czech Republic., Avigdor A; Institute of Hematology, Sheba Medical Center, Ramat Gan, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., McKinney MS; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke Cancer Institute, Durham, NC, USA., Paneesha S; Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, UK., Wahlin BE; Karolinska Institutet, Department of Medicine, Huddinge, and Karolinska University Hospital, Unit for Hematology, Stockholm, Sweden., Hrom JS; Forrest General Hospital and Hattiesburg Clinic of Hematology and Oncology, Hattiesburg, MS, USA., Cunningham D; Royal Marsden Hospital, NHS Foundation Trust, London and Surrey, UK., Morley N; Sheffield Teaching Hospital, NHS Foundation Trust, Sheffield and London, UK., Canales M; Hospital Universitario La Paz, Madrid, Spain., Bastos-Oreiro M; Hematology Department, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain., Belada D; Fourth Department of Internal Medicine - Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic., Devizzi L; Division of Hemathology and Stem Cell Transplantation, IRCCS Istituto Nazionale Tumori, Milan, Italy., Zheng F; Incyte Corporation, Wilmington, DE, USA., DeMarini DJ; Incyte Corporation, Wilmington, DE, USA., Jiang W; Incyte Corporation, Wilmington, DE, USA., Jiang P; Incyte Corporation, Wilmington, DE, USA., Lynch RC; University of Washington School of Medicine, Fred Hutch Cancer Center, Seattle, WA, USA.

Publikováno v: EClinicalMedicine [EClinicalMedicine] 2023 Aug 18; Vol. 63, pp. 102130. Date of Electronic Publication: 2023 Aug 18 (Print Publication: 2023).